saikosaponin d has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, J; Li, R; Lv, X; Wang, H; Wang, L; You, M | 1 |
| Lee, CC; Liu, YC; Shyu, KG; Tsai, SC; Wang, BW | 1 |
2 other study(ies) available for saikosaponin d and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Saikosaponin b2 inhibits tumor angiogenesis in liver cancer via down‑regulation of VEGF/ERK/HIF‑1α signaling.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Signal Transduction; Vascular Endothelial Growth Factor A | 2023 |
Saikosaponin C induces endothelial cells growth, migration and capillary tube formation.
Topics: Antineoplastic Agents, Phytogenic; Capillaries; Cell Movement; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Endothelium, Vascular; Gene Expression; Humans; Matrix Metalloproteinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Oleanolic Acid; RNA, Messenger; Saponins; Umbilical Veins; Vascular Endothelial Growth Factor A | 2004 |